Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

Lilly

Status and phase

Completed

Phase 3

Phase 2

Conditions

Alzheimer Disease

Treatments

Drug: placebo

Drug: atomoxetine hydrochloride

Study type

Interventional

Funder types

Industry

Identifiers

NCT00191009

7951

B4Z-MC-LYCG

Details and patient eligibility

About

This study will compare atomoxetine to placebo when taken with current standard Alzheimer's Disease medications. The treatment will take approximately 6 months and it is hypothesized atomoxetine will significantly improve cognitive performance as compared to placebo.

Sex

All

Ages

55+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient presents with Alzheimer's Disease based on clinical history.
Patient must have a Mini Mental Status Score between 10 and 26.
Patient must have a reliable caregiver in frequent or daily contact with the patient.
Patient must be currently treated with and on a stable dose of a standard Alzheimer's drug treatment for at least 3 months.

Exclusion criteria

Patients who are receiving pharmacologic treatments (other than a cholinesterase inhibitor or memantine) for Alzheimer's Disease.
Patients who have a history in the past 5 years or any current evidence of major psychiatric illness.
Patients who have narrow angle glaucoma.
Patients who are experiencing clinically significant urinary hesitancy or retention as assessed by a physician.